EMA Authorised: Alyftrek (deutivacaftor;tezacaftor;vanzacaftor calcium dihydrate) — Vertex Pharmaceuticals (Ireland) Limited

View source ↗

Summary

Alyftrek has been authorised in the EU for cystic fibrosis under Vertex Pharmaceuticals, with orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)
• deutivacaftor;tezacaftor;vanzacaftor calcium dihydrate

Snippet

Status: Authorised. Therapeutic area: Cystic Fibrosis. MAH: Vertex Pharmaceuticals (Ireland) Limited. Decision date: 23/07/2026. Orphan medicine